Sugi Predict

Sugi Predict / Compounds / SCHEMBL21528073

SCHEMBL21528073

SCHEMBL21528073

CC(C)(C)OC(=O)N1C[C@@H]2C[C@H]1CN2CCOCCOCCNC(=O)OCc1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 1/20 0.51
▸ SMN1; SMN2 Q16637 1/20 0.51
▸ ABCB1 P08183 1/20 0.48
▸ L3MBTL1 Q9Y468 2/20 0.40
▸ MAPT P10636 2/20 0.40
▸ KEAP1 Q14145 1/20 0.40
▸ NFE2L2 Q16236 1/20 0.40
▸ IDO1 P14902 1/20 0.39
▸ KLK7 P49862 2/20 0.39
▸ KLK5 Q9Y337 2/20 0.39
▸ GPR119 Q8TDV5 1/20 0.38
▸ SYK P43405 1/20 0.38
▸ ITGB3 P05106 1/20 0.38
▸ ITGA2B P08514 1/20 0.38
▸ HTT P42858 1/20 0.38
▸ HSD11B1 P28845 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31091787 1.00 LMNA (0.51) LMNASMN1; SMN2ABCB1L3MBTL1MAPT
SCHEMBL21528072 1.00 LMNA (0.51) LMNASMN1; SMN2ABCB1L3MBTL1MAPT
SCHEMBL5905801 0.91 ABCB1 (0.52) LMNASMN1; SMN2ABCB1L3MBTL1MAPT
SCHEMBL21528109 0.89 LMNA (0.52) LMNASMN1; SMN2ABCB1L3MBTL1MAPT
SCHEMBL30805590 0.87 LMNA (0.50) LMNASMN1; SMN2ABCB1L3MBTL1MAPT
SCHEMBL21528098 0.83 LMNA (0.59) LMNASMN1; SMN2L3MBTL1MAPTKEAP1
SCHEMBL5905807 0.80 PREP (0.50) ABCB1L3MBTL1MAPTGPR119SYK
SCHEMBL4534787 0.79 AGTR2 (0.50) SMN1; SMN2ABCB1GPR119HSD11B1
SCHEMBL22276667 0.78 LMNA (0.57) LMNASMN1; SMN2L3MBTL1
SCHEMBL21528234 0.78 LMNA (0.57) LMNASMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2026-02-10 — — US disclosed
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-04-03 — — US disclosed
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2025-01-07 — — US disclosed
CN-118978535-A C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-11-19 — — CN disclosed
CN-118894869-A C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-11-05 — — CN disclosed
EP-3788050-B1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2024-08-28 — — EP disclosed
CN-112771054-B C40-, C28-and C32-linked rapamycin analogues as mTOR inhibitors 锐新医药公司 2024-08-16 — — CN disclosed
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2024-07-30 — — US disclosed
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2024-05-23 — — US disclosed
EP-4234031-A2 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2023-08-30 — — EP disclosed
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2023-06-27 — — US disclosed
EP-3788049-B1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS REVOLUTION MEDICINES INC (US) 2023-03-29 — — EP disclosed
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2023-02-23 — — US disclosed
US-20220340596-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-10-27 — — US disclosed
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2022-06-21 — — US disclosed
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2021-11-04 — — US disclosed
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors Revolution Medicines, Inc. (US) 2021-04-20 — — US disclosed
EP-3788050-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
EP-3788049-A1 C40-, C28-, AND C-32-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS Revolution Medicines, Inc. (US) 2021-03-10 — — EP disclosed
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors Revolution Medicines, Inc. 2019-11-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685749-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885ABCB1 2980/4885
US-10980889-B1 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-20250108117-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-20210338824-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-12048749-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-12187746-B2 C26-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885ABCB1 2980/4885
US-20190336609-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-20240166667-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885ABCB1 2980/4885
US-11364300-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-20220340596-A1 C26-LINKED RAPAMYCIN ANALOGS AS MTOR INHIBITORS MTOR, RICTOR, RPTOR LMNA 3036/4885SMN1; SMN2 1321/4885ABCB1 2980/4885
US-20230055672-A1 C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors MTOR, RICTOR, RPTOR LMNA 2837/4885SMN1; SMN2 2014/4885ABCB1 3016/4885
US-12544448-B2 C40-, C28-, and C-32-linked rapamycin analogs as mTOR inhibitors RICTOR, MTOR, MLST8 LMNA 2304/4885SMN1; SMN2 1662/4885ABCB1 609/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.